Biogen’s stock stumbles as Alzheimer’s drug is rejected by European regulators
Biogen’s stock fell more than 6% premarket on Friday after European regulators gave a thumbs down to the company’s Alzheimer’s disease treatment, which it markets jointly with Eisai Co. Ltd.
